Overview

Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.

Status:
Recruiting

Trial end date:
2022-08-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the non-inferiority of Foster 100/6mg NEXThaler versus Foster 100/6mg pMDI in terms of pulmonary function in asthmatic patients, as well as the effect of the test treatments in terms of additional lung function parameters and clinical outcome measures. The purpose is also to assess the safety and tolerability.

Phase:

Phase 3

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.

Treatments:

Beclomethasone
Formoterol Fumarate